<p>药明康德（NASDAQ:OTLK - 获取免费报告）的股票目前被七家评级公司给予了 “买入” 的平均评级，Marketbeat.com 报道。七位分析师对该股票给予了买入评级。在过去一年中，覆盖该股票的经纪人给出的平均十二个月目标价为 48.20 美元。</p>
<p>获取 <strong>Outlook Therapeutics</strong> 的提醒：</p>
<ul>
<li>3 只被低估的制药股，具备上涨催化剂</li>
</ul>
<p>几位研究分析师最近对该公司进行了评论。Ascendiant Capital Markets 将药明康德的目标价从 35.00 美元下调至 33.00 美元，并在 9 月 3 日的研究报告中给予该股票 “买入” 评级。HC Wainwright 在 8 月 15 日的研究报告中重申了 “买入” 评级，并对药明康德的股票设定了 30.00 美元的目标价。Chardan Capital 在 8 月 16 日的研究报告中重新发布了 “买入” 评级，并将药明康德的目标价设定为 53.00 美元。最后，BTIG Research 在 10 月 18 日的报告中重申了 “买入” 评级，并对药明康德的股票设定了 50.00 美元的目标价。</p>
<p><strong>查看我们对药明康德的最新股票分析</strong></p>
<h2>药明康德的价格表现</h2>
<ul>
<li>MarketBeat 周报 – 6/17 - 6/21</li>
</ul>
<p>NASDAQ OTLK 的股票在周三以 5.74 美元开盘。该公司的市值为 1.3579 亿美元，市盈率为-0.50，贝塔值为 0.62。药明康德的 1 年最低价为 4.61 美元，1 年最高价为 13.32 美元。该公司的 50 日移动平均价为 6.16 美元，200 日移动平均价为 7.21 美元。</p>
<p>药明康德（NASDAQ:OTLK - 获取免费报告）最近在 8 月 14 日发布了季度财报。该公司报告每股收益（EPS）为-0.83 美元，超出市场共识预期的-1.06 美元，超出幅度为 0.23 美元。研究分析师预计药明康德在当前财年的每股收益将为-3.63 美元。</p>
<h2>药明康德的内部买卖情况</h2>
<ul>
<li>药明康德：分析师预测股票上涨超过 500%</li>
</ul>
<p>在其他药明康德的新闻中，首席财务官 Lawrence A. Kenyon 在 9 月 26 日的交易中购买了 5,000 股该股票。该股票的平均购买价格为每股 5.69 美元，总价值为 28,450.00 美元。交易后，首席财务官现在直接持有该公司 5,946 股股票，价值约为 33,832.74 美元。这代表了他们持股比例的 500.00% 的增长。此次收购在向证券交易委员会的备案中披露，相关信息可通过此链接访问。3.40% 的股票由内部人士持有。</p>
<h2>机构投资者对药明康德的看法</h2>
<p>大型投资者最近增加或减少了对该股票的持股。Great Point Partners LLC 在第二季度将其在药明康德的持股增加了 15.0%。Great Point Partners LLC 现在拥有 1,701,510 股该公司的股票，价值为 12,557,000 美元，此前在该期间内又收购了 221,510 股。Susquehanna Fundamental Investments LLC 在第二季度收购了药明康德的新股份，价值约为 303,000 美元。Squarepoint Ops LLC 在第二季度购买了药明康德的新股份，价值约为 232,000 美元。Christensen King &amp; Associates Investment Services Inc. 在第三季度收购了药明康德的新职位，价值约为 55,000 美元。最后，AQR Capital Management LLC 在第二季度购买了药明康德的新职位，价值约为 75,000 美元。11.20% 的股票由机构投资者和对冲基金持有。</p>
<h2>药明康德公司简介（获取免费报告）</h2>
<p>药明康德（Outlook Therapeutics, Inc.）是一家临床阶段的生物制药公司，专注于开发和商业化用于各种眼科适应症的单克隆抗体。其主要产品候选药物是 ONS-5010，这是一种用于治疗湿性年龄相关性黄斑变性和其他视网膜疾病的贝伐单抗眼科制剂，目前处于第三阶段临床试验中。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过药明康德</li>
<li>什么是分红竞争者？投资分红竞争者</li>
<li>麦当劳的股票在抛售和财报后是否值得购买？</li>
<li>为什么除息日对投资者来说重要？</li>
<li>QuantumScape：固态电池即将商业化</li>
<li>投资者需要了解即将上市的 IPO</li>
<li>MicroStrategy：这只比特币驱动的股票是买入还是赌博？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<p>→ 埃隆全力支持特朗普的真正原因（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTYw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTYw"/></p>
<h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
<p>在考虑药明康德之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而药明康德并不在名单上。</p>
<p>虽然药明康德目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

OTLK

<p>Outlook Therapeutics, Inc.（纳斯达克代码：OTLK）获得了七家券商的一致 “买入” 评级。分析师设定的平均十二个月目标价为 0.20 美元。最近的报告显示，Ascendiant Capital Markets 将其目标价下调至 0.00 美元，但维持 “买入” 评级。该公司的市值为 7900 万美元，报告每股收益为-0.83 美元，超出预期。首席财务官 Lawrence A. Kenyon 最近购买了 5000 股，显著增加了他的持股比例。机构投资者持有该股票的 11.20%，多家公司的持股都有显著增加</p>

<p>Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have been given an average rating of &#34;Buy&#34; by the seven ratings firms that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have covered the stock in the last year is $48.20.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:OTLK - 获取免费报告）的股票目前被七家评级公司给予了 “买入” 的平均评级，Marketbeat.com 报道。七位分析师对该股票给予了买入评级。在过去一年中，覆盖该股票的经纪人给出的平均十二个月目标价为 48.20 美元。</p>
</div><p>Get <strong>Outlook Therapeutics</strong> alerts:</p>
<ul>
<li>3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices</li>
</ul>
<div class="lb-trans"><p>获取 <strong>Outlook Therapeutics</strong> 的提醒：</p>
<ul>
<li>3 只被低估的制药股，具备上涨催化剂</li>
</ul>
</div><p>Several research analysts recently commented on the company. Ascendiant Capital Markets cut their price target on Outlook Therapeutics from $35.00 to $33.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, September 3rd. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $30.00 target price on shares of Outlook Therapeutics in a research report on Thursday, August 15th. Chardan Capital reissued a &#34;buy&#34; rating and set a $53.00 price target on shares of Outlook Therapeutics in a research report on Friday, August 16th. Finally, BTIG Research reaffirmed a &#34;buy&#34; rating and issued a $50.00 price target on shares of Outlook Therapeutics in a report on Friday, October 18th.</p>
<div class="lb-trans"><p>几位研究分析师最近对该公司进行了评论。Ascendiant Capital Markets 将药明康德的目标价从 35.00 美元下调至 33.00 美元，并在 9 月 3 日的研究报告中给予该股票 “买入” 评级。HC Wainwright 在 8 月 15 日的研究报告中重申了 “买入” 评级，并对药明康德的股票设定了 30.00 美元的目标价。Chardan Capital 在 8 月 16 日的研究报告中重新发布了 “买入” 评级，并将药明康德的目标价设定为 53.00 美元。最后，BTIG Research 在 10 月 18 日的报告中重申了 “买入” 评级，并对药明康德的股票设定了 50.00 美元的目标价。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Outlook Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对药明康德的最新股票分析</strong></p>
</div><h2>Outlook Therapeutics Price Performance</h2>
<ul>
<li>MarketBeat Week in Review – 6/17 - 6/21</li>
</ul>
<div class="lb-trans"><h2>药明康德的价格表现</h2>
<ul>
<li>MarketBeat 周报 – 6/17 - 6/21</li>
</ul>
</div><p>Shares of NASDAQ OTLK opened at $5.74 on Wednesday. The company has a market capitalization of $135.79 million, a price-to-earnings ratio of -0.50 and a beta of 0.62. Outlook Therapeutics has a 1-year low of $4.61 and a 1-year high of $13.32. The business has a 50-day moving average of $6.16 and a 200-day moving average of $7.21.</p>
<div class="lb-trans"><p>NASDAQ OTLK 的股票在周三以 5.74 美元开盘。该公司的市值为 1.3579 亿美元，市盈率为-0.50，贝塔值为 0.62。药明康德的 1 年最低价为 4.61 美元，1 年最高价为 13.32 美元。该公司的 50 日移动平均价为 6.16 美元，200 日移动平均价为 7.21 美元。</p>
</div><p>Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.23. Research analysts expect that Outlook Therapeutics will post -3.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:OTLK - 获取免费报告）最近在 8 月 14 日发布了季度财报。该公司报告每股收益（EPS）为-0.83 美元，超出市场共识预期的-1.06 美元，超出幅度为 0.23 美元。研究分析师预计药明康德在当前财年的每股收益将为-3.63 美元。</p>
</div><h2>Insider Buying and Selling at Outlook Therapeutics</h2>
<ul>
<li>Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside</li>
</ul>
<div class="lb-trans"><h2>药明康德的内部买卖情况</h2>
<ul>
<li>药明康德：分析师预测股票上涨超过 500%</li>
</ul>
</div><p>In other Outlook Therapeutics news, CFO Lawrence A. Kenyon acquired 5,000 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was acquired at an average price of $5.69 per share, with a total value of $28,450.00. Following the transaction, the chief financial officer now directly owns 5,946 shares in the company, valued at approximately $33,832.74. This represents a 500.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. 3.40% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他药明康德的新闻中，首席财务官 Lawrence A. Kenyon 在 9 月 26 日的交易中购买了 5,000 股该股票。该股票的平均购买价格为每股 5.69 美元，总价值为 28,450.00 美元。交易后，首席财务官现在直接持有该公司 5,946 股股票，价值约为 33,832.74 美元。这代表了他们持股比例的 500.00% 的增长。此次收购在向证券交易委员会的备案中披露，相关信息可通过此链接访问。3.40% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Outlook Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对药明康德的看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the stock. Great Point Partners LLC increased its holdings in shares of Outlook Therapeutics by 15.0% in the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company's stock worth $12,557,000 after acquiring an additional 221,510 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Outlook Therapeutics in the second quarter valued at approximately $303,000. Squarepoint Ops LLC bought a new stake in shares of Outlook Therapeutics during the second quarter valued at approximately $232,000. Christensen King &amp; Associates Investment Services Inc. acquired a new position in shares of Outlook Therapeutics during the third quarter worth approximately $55,000. Finally, AQR Capital Management LLC bought a new position in Outlook Therapeutics in the 2nd quarter worth approximately $75,000. 11.20% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该股票的持股。Great Point Partners LLC 在第二季度将其在药明康德的持股增加了 15.0%。Great Point Partners LLC 现在拥有 1,701,510 股该公司的股票，价值为 12,557,000 美元，此前在该期间内又收购了 221,510 股。Susquehanna Fundamental Investments LLC 在第二季度收购了药明康德的新股份，价值约为 303,000 美元。Squarepoint Ops LLC 在第二季度购买了药明康德的新股份，价值约为 232,000 美元。Christensen King &amp; Associates Investment Services Inc. 在第三季度收购了药明康德的新职位，价值约为 55,000 美元。最后，AQR Capital Management LLC 在第二季度购买了药明康德的新职位，价值约为 75,000 美元。11.20% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Outlook Therapeutics Company Profile (Get Free Report</h2>
<div class="lb-trans"><h2>药明康德公司简介（获取免费报告）</h2>
</div><p>Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.</p>
<div class="lb-trans"><p>药明康德（Outlook Therapeutics, Inc.）是一家临床阶段的生物制药公司，专注于开发和商业化用于各种眼科适应症的单克隆抗体。其主要产品候选药物是 ONS-5010，这是一种用于治疗湿性年龄相关性黄斑变性和其他视网膜疾病的贝伐单抗眼科制剂，目前处于第三阶段临床试验中。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Outlook Therapeutics</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>Is McDonald's Stock a Smart Buy After Sell-Off and Earnings?</li>
<li>Why is the Ex-Dividend Date Significant to Investors?</li>
<li>QuantumScape: Solid State EV Batteries Nearing Commercialization</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过药明康德</li>
<li>什么是分红竞争者？投资分红竞争者</li>
<li>麦当劳的股票在抛售和财报后是否值得购买？</li>
<li>为什么除息日对投资者来说重要？</li>
<li>QuantumScape：固态电池即将商业化</li>
<li>投资者需要了解即将上市的 IPO</li>
<li>MicroStrategy：这只比特币驱动的股票是买入还是赌博？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OTLK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><p>→ The real reason Elon is fully endorsing Trump (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 埃隆全力支持特朗普的真正原因（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTYw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9960&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Outlook Therapeutics right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
</div><p>Before you consider Outlook Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑药明康德之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outlook Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而药明康德并不在名单上。</p>
</div><p>While Outlook Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然药明康德目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Outlook Therapeutics, Inc.（纳斯达克股票代码：OTLK）获得券商一致推荐的 “买入” 评级